Head-to-head comparison
| Property | Leuprolide | Cetrorelix |
|---|---|---|
| Category | Other | Other |
| Legal Status | Prescription | Prescription |
| Primary Route | subcutaneous | subcutaneous |
| Half-life | ~3 hours (IV bolus); sustained release over weeks with depot formulations | ~5 hours (0.25 mg dose); ~30 hours (3 mg dose) |
| Mol. Weight | 1,209.4 Da | 1,431.04 Da |
| Side Effects | Hot flashes, Testosterone/estrogen suppression (intended), Sexual dysfunction / decreased libido | Injection site reactions (redness, swelling, itching), Nausea, Headache |
Key differences
- Mechanism: Leuprolide binds and continuously activates the GnRH receptor, causing an initial LH/FSH surge (flare) followed by receptor desensitization and profound gonadotropin suppression after 1-3 weeks; cetrorelix competitively blocks the receptor, suppressing LH and FSH within hours with no flare.
- Onset of suppression: GnRH agonists require 1-3 weeks of paradoxical stimulation before suppression sets in; GnRH antagonists produce clinically meaningful LH suppression within hours of the first dose.
- Prostate cancer use: In metastatic hormone-sensitive prostate cancer, GnRH agonists are started with an antiandrogen (bicalutamide, flutamide) for the first weeks to block flare-induced testosterone surge; GnRH antagonists like degarelix are preferred in high-burden disease where flare is unacceptable.
- IVF protocol shape: Agonist (long) protocols require 2-3 weeks of pituitary downregulation before stimulation; antagonist protocols start stimulation first and add the antagonist mid-cycle to block the LH surge, typically 4-5 days shorter and with lower OHSS risk.
- Endometriosis and fibroids: GnRH agonists (leuprolide depot, goserelin) are the established parenteral option for durable ovarian suppression with add-back therapy; IV/SC antagonists are not standard here, though oral antagonists now fill this niche.
- Pediatric central precocious puberty: Long-acting GnRH agonist formulations (leuprolide depot, histrelin implant) are the standard; GnRH antagonists are not the standard pediatric option.
- Side-effect onset: Both classes induce menopausal-type symptoms (hot flashes, bone loss, mood effects) once suppression is established, but antagonists avoid the transient flare-related symptom worsening that agonists produce at initiation.
The verdict
GnRH agonists and antagonists are not interchangeable — they are chosen by indication. Agonists (leuprolide, goserelin, triptorelin) dominate endometriosis, fibroids, central precocious puberty, and standard-risk prostate cancer, where the flare is manageable and long-acting depot formulations give months of coverage from a single injection. Antagonists (cetrorelix, ganirelix in IVF; degarelix, relugolix in prostate cancer) are preferred when flare would be harmful or when rapid, reversible suppression matters — high-burden metastatic prostate cancer, antagonist IVF protocols, and short-course hormonal control. The emergence of oral GnRH antagonists (relugolix, elagolix) has extended antagonist use into endometriosis and fibroids, territory historically owned by injectable agonists.
Frequently asked questions
GnRH agonists have long-acting depot formulations (1, 3, 4, and 6-month leuprolide depots, 12-month histrelin implant) that give sustained suppression from a single injection or implant — a major convenience advantage for chronic use. Cetrorelix and ganirelix are short-acting injections. Faster onset matters less in chronic endometriosis or precocious puberty, where the goal is months of stable suppression.
Cetrorelix itself is not a standard prostate cancer agent. The GnRH antagonist used for prostate cancer is degarelix (injectable depot) or relugolix (oral). Cetrorelix is primarily an IVF-era antagonist used to block the LH surge during controlled ovarian stimulation. The class rationale for prostate cancer — no flare — applies, but degarelix and relugolix are the agents that carried that advantage into oncology.
Flare is the initial paradoxical LH and FSH surge that GnRH agonists produce before desensitization suppresses gonadotropins. In prostate cancer with bone metastases, the testosterone surge can worsen pain, cause urinary obstruction, or precipitate spinal cord compression. In IVF, an unblocked LH surge can trigger premature ovulation. Flare is the single biggest clinical reason to pick an antagonist over an agonist.
Once gonadotropin suppression is established, both classes produce the same downstream hypogonadal side-effect profile — hot flashes, bone mineral density loss with prolonged use, sexual side effects, and mood changes. The difference is onset shape: agonists may cause symptom worsening during the flare phase, antagonists go straight into the hypogonadal state.
GnRH antagonist protocols (cetrorelix, ganirelix) have become the more common IVF protocol shape in many centers because they shorten cycles, reduce total gonadotropin usage, and lower OHSS risk. Long agonist protocols remain in use for specific patient profiles (endometriosis-associated infertility, certain poor-responder strategies), but antagonist protocols are the default in most modern IVF programs.
Yes. Elagolix (Orilissa) is approved for endometriosis-associated pain and uterine fibroids. Relugolix is approved for advanced prostate cancer (Orgovyx) and, in combination with estradiol and norethindrone (Myfembree, Ryeqo), for fibroids and endometriosis. These oral antagonists have brought non-flare, rapid-onset pituitary suppression into chronic indications previously dominated by injectable agonists.